Clinical and pathogenetic features of cerebral stroke in patients with new corоnavirus infection (COVID-19)

Андреев, В. В.; Podunov, Alexander Y.; Lapin, D. S.; Gilyaeva, Z. L.; Nikiforova, E. N.; Golikov, K. V.; Руденко, Д. И.

doi:10.24884/1682-6655-2020-19-3-46-56

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Характерним феноменом при вірусних захворюваннях є порушення кровообігу головного мозку на рівні мікроциркуляції, що пов'язане з ураженням артеріол і капілярів, а також порушення реологічних властивостей крові [5]. Слід зазначити, що при такому захворюванні, як COVID-19, ураження судин, які забезпечують кровообіг ЦНС, і дистрофічно-деструктивні зміни у нейронах «накладаються» на токсигенний та гіпоксичний чинники.…”

Section: результати та їх обговоренняunclassified

«Постковідний Синдром»: Неврологічні Прояви Та Лікування Українським Препаратом Когнум

2021

UMJ

View full text Add to dashboard Cite

Section: результати та їх обговоренняunclassified

«Постковідний Синдром»: Неврологічні Прояви Та Лікування Українським Препаратом Когнум

2021

UMJ

View full text Add to dashboard Cite

Neurological Complications and Consequences of the Novel Coronavirus COVID-19 Infection in Elderly and Senile Patients (Literature Review)

Флуд

Shcherbuk²,

Shcherbuk³

et al. 2022

Adv Gerontol

View full text Add to dashboard Cite

Based on available publications, the article systematizes information about some forms of lesions of the central nervous system (CNS), their pathogenesis and clinical manifestations in the case of COVID-19. The risk factors, mechanisms of development, diagnostic approach, and the age characteristics of patients with neurological complications of COVID-19 are discussed. The specific mechanisms of the neuroinvasiveness and neurovirulence of the SARS-CoV-2 virus, regardless of the age of patients and the presence of risk factors, lead to systemic damage to the endothelium of small-caliber vessels, generalized thrombovasculitis, and an increased risk of ischemic and hemorrhagic strokes. At the same time, the most vulnerable category is elderly and senile patients with cardiovascular and metabolic disorders (arterial hypertension, obesity, diabetes mellitus), which sharply worsen treatment outcomes. The clinical experience accumulated during the COVID-19 pandemic indicates the development of the following most frequent post-covid neurological complications and consequences in mainly elderly and senile patients: cranial mononeuropathies, chemosensory dysfunction, encephalopathy, insomnia, stroke, acute meningoencephalitis, acute disseminated encephalomyelitis, acute polyneuropathy Guillain–Barré syndrome, and transverse myelitis. The benefits of vaccination against COVID-19 far outweigh the risks of possible post-vaccination neurological complications and consequences, especially in elderly and senile patients.

show abstract

Anticoagulant therapy for stroke prevention in patients with severe COVID-19

Azimov

Rakhimbaeva

Azimov

2021

RJTAO

View full text Add to dashboard Cite

During the pandemic of the new coronavirus infection, there is increasing evidence of neurological complications associated with COVID-19. There is no doubt that stroke can be a major complication in patients with severe disease course.Objective: to determine the safest and most effective anticoagulant for stroke prevention in patients with severe COVID-19.Patients and methods. A prospective study enrolled 520 patients with severe COVID-19. We used the following criteria for severe COVID-19: SpO2 <92% on room air at sea level, PaO2 /FiO2 <300 mm Hg, respiratory rate >30 breaths/min, lung infiltrates >50% on computed tomography. The study included 509 patients, divided into three groups depending on the type of anticoagulant therapy: patients of the 1st group received 24–36 thousand IU of heparin, patients of the 2nd group – enoxaparin at a dose of 1 mg/kg per day, patients of the 3rd group – rivaroxaban at a dose of 20 mg/day. The duration of anticoagulant administration depended on the severity of the patient's condition, dynamics of laboratory parameters (D-dimer, fibrinogen, international normalized ratio, activated partial thromboplastin time, platelet count), and varied from 2 to 6 weeks. In addition, we studied the incidence of ischemic and hemorrhagic strokes and transient ischemic attacks during a 6-week follow-up period. The article also presents a clinical case of large artery thrombosis in a young patient with severe COVID-19 without stroke risk factors.Results and discussion. Even against the background of active primary prevention, stroke incidence was 2.6% (0.6% for ischemic stroke, 1.4% for venous stroke, and 0.6% for hemorrhagic stroke). The highest stroke incidence was observed in the group of patients receiving heparin. In contrast, the prevention of thrombotic complications in patients receiving low-molecular-weight anticoagulants or rivaroxaban showed the best results with minimal morbidity and mortality in severe COVID-19.Conclusion. Stroke can be a complication of COVID-19, and preventive anticoagulant therapy using low-molecular-weight heparin or a factor X inhibitor effectively prevents this complication.

show abstract

Clinical and pathogenetic features of cerebral stroke in patients with new corоnavirus infection (COVID-19)

Cited by 6 publications

References 8 publications

«Постковідний Синдром»: Неврологічні Прояви Та Лікування Українським Препаратом Когнум

«Постковідний Синдром»: Неврологічні Прояви Та Лікування Українським Препаратом Когнум

Neurological Complications and Consequences of the Novel Coronavirus COVID-19 Infection in Elderly and Senile Patients (Literature Review)

Anticoagulant therapy for stroke prevention in patients with severe COVID-19

Contact Info

Product

Resources

About